Open AccessCLINICAL EXPERIENCE OF THE USE OF PD-1 INHIBITOR IN PATIENTS WITH NON-CELL LUNG CANCER WITH METASTATIC DAMAGE OF KIDNEYS AND ADRENALS
Author(s) -
Ksenya A. Sarantseva,
D. I. Yudin,
Mariya Okruzhnova,
К. П. Лактионов
Publication year - 2017
Publication title -
rossijskij onkologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2412-9119
pISSN - 1028-9984
DOI - 10.18821/1028-9984-2017-22-5-250-254
Subject(s) - nivolumab , medicine , lung cancer , immunotherapy , oncology , chemotherapy , clinical trial , cancer , lung
Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. A new promising direction of NSCLC treatment in the second line is the use of immunotherapy by inhibitors of immune control points. This group of drugs radically changed the outlook on the prognosis of patients with disseminated NSCLC progressing on previous platinum-containing chemotherapy. The article presents the results of a clinical trial program for nivolumab and the analysis of clinical cases of its application in NSCLC patients with metastatic damage of the kidneys and adrenal glands.